Search Results - "Rodig, Scott J"

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma by Chapuy, Bjoern, McKeown, Michael R., Lin, Charles Y., Monti, Stefano, Roemer, Margaretha G.M., Qi, Jun, Rahl, Peter B., Sun, Heather H., Yeda, Kelly T., Doench, John G., Reichert, Elaine, Kung, Andrew L., Rodig, Scott J., Young, Richard A., Shipp, Margaret A., Bradner, James E.

“…Diffuse large B cell lymphoma (DLBCL) is a biologically heterogeneous and clinically aggressive disease. Here, we explore the role of bromodomain and…”
Get full text

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma by Rodig, Scott J, Gusenleitner, Daniel, Jackson, Donald G, Gjini, Evisa, Giobbie-Hurder, Anita, Jin, Chelsea, Chang, Han, Lovitch, Scott B, Horak, Christine, Weber, Jeffrey S, Weirather, Jason L, Wolchok, Jedd D, Postow, Michael A, Pavlick, Anna C, Chesney, Jason, Hodi, F Stephen

“…Combination anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1) therapy promotes antitumor immunity and provides…”
Get more information

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study by Ansell, Stephen M, Minnema, Monique C, Johnson, Peter, Timmerman, John M, Armand, Philippe, Shipp, Margaret A, Rodig, Scott J, Ligon, Azra H, Roemer, Margaretha G M, Reddy, Nishitha, Cohen, Jonathon B, Assouline, Sarit, Poon, Michelle, Sharma, Manish, Kato, Kazunobu, Samakoglu, Selda, Sumbul, Anne, Grigg, Andrew

“…Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1…”
Get full text

The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma In Vivo by Karreth, Florian A., Reschke, Markus, Ruocco, Anna, Ng, Christopher, Chapuy, Bjoern, Léopold, Valentine, Sjoberg, Marcela, Keane, Thomas M., Verma, Akanksha, Ala, Ugo, Tay, Yvonne, Wu, David, Seitzer, Nina, Velasco-Herrera, Martin Del Castillo, Bothmer, Anne, Fung, Jacqueline, Langellotto, Fernanda, Rodig, Scott J., Elemento, Olivier, Shipp, Margaret A., Adams, David J., Chiarle, Roberto, Pandolfi, Pier Paolo

“…Research over the past decade has suggested important roles for pseudogenes in physiology and disease. In vitro experiments demonstrated that pseudogenes…”
Get full text

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome by Roemer, Margaretha G M, Advani, Ranjana H, Ligon, Azra H, Natkunam, Yasodha, Redd, Robert A, Homer, Heather, Connelly, Courtney F, Sun, Heather H, Daadi, Sarah E, Freeman, Gordon J, Armand, Philippe, Chapuy, Bjoern, de Jong, Daphne, Hoppe, Richard T, Neuberg, Donna S, Rodig, Scott J, Shipp, Margaret A

“…Classical Hodgkin lymphomas (cHLs) include small numbers of malignant Reed-Sternberg cells within an extensive but ineffective inflammatory/immune cell…”
Get full text

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma by Carey, Christopher D., Gusenleitner, Daniel, Lipschitz, Mikel, Roemer, Margaretha G.M., Stack, Edward C., Gjini, Evisa, Hu, Xihao, Redd, Robert, Freeman, Gordon J., Neuberg, Donna, Hodi, F. Stephen, Liu, Xiaole Shirley, Shipp, Margaret A., Rodig, Scott J.

“…Signaling between programmed cell death protein 1 (PD-1) and the PD-1 ligands (PD-L1, PD-L2) is essential for malignant Hodgkin Reed-Sternberg (HRS) cells to…”
Get full text

Implications of the tumor immune microenvironment for staging and therapeutics by Taube, Janis M, Galon, Jérôme, Sholl, Lynette M, Rodig, Scott J, Cottrell, Tricia R, Giraldo, Nicolas A, Baras, Alexander S, Patel, Sanjay S, Anders, Robert A, Rimm, David L, Cimino-Mathews, Ashley

“…Characterizing the tumor immune microenvironment enables the identification of new prognostic and predictive biomarkers, the development of novel therapeutic…”
Get full text

The biology and treatment of EML4-ALK non-small cell lung cancer by Sasaki, Takaaki, Rodig, Scott J, Chirieac, Lucian R, Jänne, Pasi A

“…Abstract The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a…”
Get full text

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma by Roemer, Margaretha G M, Redd, Robert A, Cader, Fathima Zumla, Pak, Christine J, Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Anas, Fanale, Michelle, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John, Collins, Graham P, Ramchandren, Radhakrishnan, Cohen, Jonathon B, De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J, Trneny, Marek, Ansell, Stephen, Kato, Kazunobu, Farsaci, Benedetto, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S, Pinkus, Geraldine S, Ligon, Azra H, Rodig, Scott J, Shipp, Margaret A

“…Purpose Hodgkin Reed-Sternberg (HRS) cells evade antitumor immunity by multiple means, including gains of 9p24.1/ CD274(PD-L1)/ PDCD1LG2(PD-L2) and perturbed…”
Get full text

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity by Jacobson, Caron A, Hunter, Bradley D, Redd, Robert, Rodig, Scott J, Chen, Pei-Hsuan, Wright, Kyle, Lipschitz, Mikel, Ritz, Jerome, Kamihara, Yusuke, Armand, Philippe, Nikiforow, Sarah, Rogalski, Michael, Maakaron, Joseph, Jaglowski, Samantha, Maus, Marcela V, Chen, Yi-Bin, Abramson, Jeremy S, Kline, Justin, Budde, Elizabeth, Herrera, Alex, Mei, Matthew, Cohen, Jonathon B, Smith, Stephen D, Maloney, David G, Gopal, Ajay K, Frigault, Matthew J, Acharya, Utkarsh H

“…Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of…”
Get full text

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints by Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J., Rodig, Scott J., Asahina, Hajime, Jones, Robert E., Kulkarni, Meghana M., Kuraguchi, Mari, Palakurthi, Sangeetha, Fecci, Peter E., Johnson, Bruce E., Janne, Pasi A., Engelman, Jeffrey A., Gangadharan, Sidharta P., Costa, Daniel B., Freeman, Gordon J., Bueno, Raphael, Hodi, F. Stephen, Dranoff, Glenn, Wong, Kwok-Kin, Hammerman, Peter S.

“…Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung…”
Get full text

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study by Ramchandren, Radhakrishnan, Domingo-Domènech, Eva, Rueda, Antonio, Trněný, Marek, Feldman, Tatyana A, Lee, Hun Ju, Provencio, Mariano, Sillaber, Christian, Cohen, Jonathon B, Savage, Kerry J, Willenbacher, Wolfgang, Ligon, Azra H, Ouyang, Jing, Redd, Robert, Rodig, Scott J, Shipp, Margaret A, Sacchi, Mariana, Sumbul, Anne, Armand, Philippe, Ansell, Stephen M

“…Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed/refractory classic Hodgkin lymphoma…”
Get full text

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies by CHEN, Benjamin J, CHAPUY, Bjoern, RODIG, Scott J, OUYANG, Jing, SUN, Heather H, ROEMER, Margaretha G. M, XU, Mina L, HONGBO YU, FLETCHER, Christopher D. M, FREEMAN, Gordon J, SHIPP, Margaret A

“…Programmed cell death ligand 1 (PD-L1) is an immunomodulatory molecule expressed by antigen-presenting cells and select tumors that engages receptors on T…”
Get full text

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma by Green, Michael R., Monti, Stefano, Rodig, Scott J., Juszczynski, Przemyslaw, Currie, Treeve, O'Donnell, Evan, Chapuy, Bjoern, Takeyama, Kunihiko, Neuberg, Donna, Golub, Todd R., Kutok, Jeffery L., Shipp, Margaret A.

“…Classical Hodgkin lymphoma (cHL) and mediastinal large B-cell lymphoma (MLBCL) are lymphoid malignancies with certain shared clinical, histologic, and…”
Get full text

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia by Treon, Steven P, Xu, Lian, Yang, Guang, Zhou, Yangsheng, Liu, Xia, Cao, Yang, Sheehy, Patricia, Manning, Robert J, Patterson, Christopher J, Tripsas, Christina, Arcaini, Luca, Pinkus, Geraldine S, Rodig, Scott J, Sohani, Aliyah R, Harris, Nancy Lee, Laramie, Jason M, Skifter, Donald A, Lincoln, Stephen E, Hunter, Zachary R

“…Waldenström's macroglobulinemia is a lymphoplasmacytic lymphoma. Genetic analysis has revealed a common mutation (L265P) in MYD88 in more than 90% of patients…”
Get full text

Tet1 and Tet2 Regulate 5-Hydroxymethylcytosine Production and Cell Lineage Specification in Mouse Embryonic Stem Cells by Koh, Kian Peng, Yabuuchi, Akiko, Rao, Sridhar, Huang, Yun, Cunniff, Kerrianne, Nardone, Julie, Laiho, Asta, Tahiliani, Mamta, Sommer, Cesar A., Mostoslavsky, Gustavo, Lahesmaa, Riitta, Orkin, Stuart H., Rodig, Scott J., Daley, George Q., Rao, Anjana

“…TET family enzymes convert 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA. Here, we show that Tet1 and Tet2 are Oct4-regulated enzymes that…”
Get full text

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma by Armand, Philippe, Janssens, Ann, Gritti, Giuseppe, Radford, John, Timmerman, John, Pinto, Antonio, Mercadal Vilchez, Santiago, Johnson, Peter, Cunningham, David, Leonard, John P., Rodig, Scott J., Martín-Regueira, Patricia, Sumbul, Anne, Samakoglu, Selda, Tang, Hao, Ansell, Stephen M.

“…Nivolumab, an anti–programmed death-1 (PD-1) monoclonal antibody, showed promising activity in relapsed or refractory (R/R) follicular lymphoma (FL) in a phase…”
Get full text

BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia by Ott, Christopher J., Kopp, Nadja, Bird, Liat, Paranal, Ronald M., Qi, Jun, Bowman, Teresa, Rodig, Scott J., Kung, Andrew L., Bradner, James E., Weinstock, David M.

“…We investigated the therapeutic potential of JQ1, an inhibitor of the BET class of human bromodomain proteins, in B-cell acute lymphoblastic leukemia (B-ALL)…”
Get full text

Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo by YANSHENG HAO, BJOERN CHAPUY, MONTI, Stefano, SUN, Heather H, RODIG, Scott J, SHIPP, Margaret A

“…Classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (MLBCL) share similar histologic, clinical, and genetic features. In recent…”
Get full text

SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas by Chen, Linfeng, Monti, Stefano, Juszczynski, Przemyslaw, Ouyang, Jing, Chapuy, Bjoern, Neuberg, Donna, Doench, John G., Bogusz, Agata M., Habermann, Thomas M., Dogan, Ahmet, Witzig, Thomas E., Kutok, Jeffery L., Rodig, Scott J., Golub, Todd, Shipp, Margaret A.

“…B cell receptor (BCR) signaling pathway components represent promising treatment targets in diffuse large B cell lymphoma (DLBCL) and additional B cell tumors…”
Get full text